Trial Profile

A Continued Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of PLN-74809 in Healthy Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 May 2022 According to a Pliant Therapeutics media release, data from this study were presented at the 2022 American Thoracic Society (ATS) International Conference.
09 Aug 2021 According to a Pliant Therapeutics media release, PLN-74809 has completed dosing of additional SAD cohorts of up to 640 mg and MAD cohorts of up to 320 mg once daily dose in an extended dose escalation trial.
10 Nov 2020 According to a Pliant Therapeutics media release, dosing has been completed in multiple ascending dose cohorts of 120mg and 160mg once daily in an extended dose escalation trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com